Outcome of Chronic Myeloid Leukemia Patients with Early Molecular Response at 3 and 6 months: a Comparative Analysis of Generic Imatinib and Glivec

We retrospectively evaluated 90 patients with chronic myeloid leukemia (CML) receiving both upfront original imatinib (OI) and generic imatinib (GI) for the impact of early molecular response on long-term outcome. We demonstrated that achieving optimal response at 3 and 6 months in patients receiving both first-line GI and OI was clearly associated with higher response and event-free survival rates.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2017 Category: Hematology Authors: Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafe Source Type: research